Načítá se...
Aminopyridines for symptomatic treatment in multiple sclerosis
BACKGROUND: The potassium channel blockers 4‐aminopyridine (AP) and 3,4‐diaminopyridine (DAP) increase nerve conduction in demyelinated nerve fibers, and have been proposed as a symptomatic therapy for people with multiple sclerosis (MS). OBJECTIVES: To determine the efficacy and safety of aminopyri...
Uloženo v:
| Vydáno v: | Cochrane Database Syst Rev |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley & Sons, Ltd
2002
|
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7047571/ https://ncbi.nlm.nih.gov/pubmed/11687106 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD001330 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|